Georg Kuhnert

2.2k total citations · 1 hit paper
23 papers, 963 citations indexed

About

Georg Kuhnert is a scholar working on Pathology and Forensic Medicine, Pulmonary and Respiratory Medicine and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Georg Kuhnert has authored 23 papers receiving a total of 963 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Pathology and Forensic Medicine, 15 papers in Pulmonary and Respiratory Medicine and 15 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Georg Kuhnert's work include Lymphoma Diagnosis and Treatment (18 papers), Lung Cancer Treatments and Mutations (13 papers) and Medical Imaging Techniques and Applications (12 papers). Georg Kuhnert is often cited by papers focused on Lymphoma Diagnosis and Treatment (18 papers), Lung Cancer Treatments and Mutations (13 papers) and Medical Imaging Techniques and Applications (12 papers). Georg Kuhnert collaborates with scholars based in Germany, Netherlands and Switzerland. Georg Kuhnert's co-authors include Markus Dietlein, Carsten Kobe, Alexander Drzezga, Andreas Engert, Peter Borchmann, Bernd Neumaier, Dennis A. Eichenauer, Raphael Richarz, Thomas Fischer and Philipp Krapf and has published in prestigious journals such as Journal of Clinical Oncology, Blood and The Lancet Oncology.

In The Last Decade

Georg Kuhnert

19 papers receiving 947 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Comparison of [18F]DCFPyL and [68Ga]Ga-PSMA-HBED-CC for PSMA-PET Imaging in Patients with Relapsed Prostate Cancer

2015 286 citations Markus Dietlein, Carsten Kobe et al. Molecular Imaging and Biology profile →

Peers

Countries citing papers authored by Georg Kuhnert

Since Specialization

Citations

This map shows the geographic impact of Georg Kuhnert's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Georg Kuhnert with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Georg Kuhnert more than expected).

Fields of papers citing papers by Georg Kuhnert

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Georg Kuhnert. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Georg Kuhnert. The network helps show where Georg Kuhnert may publish in the future.

Co-authorship network of co-authors of Georg Kuhnert

This figure shows the co-authorship network connecting the top 25 collaborators of Georg Kuhnert. A scholar is included among the top collaborators of Georg Kuhnert based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Georg Kuhnert. Georg Kuhnert is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	PET-Guided Treatment of Early-Stage Favorable Hodgkin Lymphoma: Final Results of the International, Randomized Phase 3 Trial HD16 by the GHSG 2019 ·International Journal of Radiation OncologyBiologyPhysics ·Hans Theodor Eich, Christian Baues, Michael Fuchs, Carsten Kobe, Richard Greil, Stephanie Sasse, Josée M. Zijlstra, Andreas Lohri, Andreas Rosenwald, Bastian von Tresckow, Volker Diehl, Georg Kuhnert, Markus Dietlein, Peter Borchmann, Andreas Engert	3
2	Metabolic Tumor Volume for Response Prediction in Advanced-Stage Hodgkin Lymphoma 2018 ·Journal of Nuclear Medicine ·Jasmin Mettler, Horst Müller, Conrad‐Amadeus Voltin, Christian Baues, Bernd Klaeser, Alden A. Moccia, Peter Borchmann, Andreas Engert, Georg Kuhnert, Alexander Drzezga, Markus Dietlein, Carsten Kobe	59
3	Quantitative assessment of 18F-FDG PET in patients with Hodgkin lymphoma 2018 ·Nuclear Medicine Communications ·Conrad‐Amadeus Voltin, Jasmin Mettler, Ronald Boellaard, Georg Kuhnert, Markus Dietlein, Peter Borchmann, Alexander Drzezga, Carsten Kobe	6
4	Outcome-based interpretation of early interim PET in advanced-stage Hodgkin lymphoma 2018 ·Blood ·Carsten Kobe, Helen Goergen, Christian Baues, Georg Kuhnert, Conrad‐Amadeus Voltin, Josée M. Zijlstra, Otto S. Hoekstra, Jasmin Mettler, Alexander Drzezga, Andreas Engert, Peter Borchmann, Markus Dietlein	25
5	PET-Guided Treatment of Early-Stage Favorable Hodgkin Lymphoma: Final Results of the International, Randomized Phase 3 Trial HD16 By the German Hodgkin Study Group 2018 ·Blood ·Michael Fuchs, Helen Goergen, Carsten Kobe, Hans Theodor Eich, Christian Baues, Richard Greil, Stephanie Sasse, Josée M. Zijlstra, Andreas Lohri, Andreas Rosenwald, Bastian von Tresckow, Volker Diehl, Georg Kuhnert, Markus Dietlein, Peter Borchmann, Andreas Engert	12
6	Incorporation of brentuximab vedotin into first-line treatment of advanced classical Hodgkin's lymphoma: final analysis of a phase 2 randomised trial by the German Hodgkin Study Group 2017 ·The Lancet Oncology ·Dennis A. Eichenauer, Annette Plütschow, Stefanie Kreissl, Martin Sökler, Johannes C. Hellmuth, Julia Meißner, Stephan Mathas, Max S. Topp, Karolin Behringer, Wolfram Klapper, Georg Kuhnert, Markus Dietlein, Carsten Kobe, Michael Fuchs, Volker Diehl, Andreas Engert, Peter Borchmann	70
7	In vivo Patterns of Tau Pathology, Amyloid-β Burden, and Neuronal Dysfunction in Clinical Variants of Alzheimer’s Disease 2016 ·Journal of Alzheimer s Disease ·Julian Dronse, Klaus Fließbach, Gérard N. Bischof, Boris von Reutern, Jennifer Faber, Jochen Hammes, Georg Kuhnert, Bernd Neumaier, Oezguer A. Onur, Juraj Kukolja, Thilo van Eimeren, Frank Jessen, Gereon R. Fink, Thomas Klockgether, Alexander Drzezga	90
8	Concordance in the interpretation of PET after chemotherapy in advanced stage Hodgkin lymphoma 2015 ·Nuklearmedizin - NuclearMedicine ·Georg Kuhnert, Heinz Haverkamp, Michael Fuchs, Deniz Kahraman, (unknown), (unknown), Christian Baues, (unknown), Paul J. Bröckelmann, Peter Borchmann, Alexander Drzezga, Andreas Engert, Markus Dietlein, Carsten Kobe	3
9	Comparison of [18F]DCFPyL and [68Ga]Ga-PSMA-HBED-CC for PSMA-PET Imaging in Patients with Relapsed Prostate Cancer breakdown → 2015 ·Molecular Imaging and Biology ·Markus Dietlein, Carsten Kobe, Georg Kuhnert, (unknown), Thomas Fischer, Klaus Schomäcker, Matthias Schmidt, Felix Dietlein, Boris D. Zlatopolskiy, Philipp Krapf, Raphael Richarz, Stephan Neubauer, Alexander Drzezga, Bernd Neumaier	286
10	Impact of PET/CT image reconstruction methods and liver uptake normalization strategies on quantitative image analysis 2015 ·European Journal of Nuclear Medicine and Molecular Imaging ·Georg Kuhnert, Ronald Boellaard, (unknown), Deniz Kahraman, Matthias Scheffler, Jürgen Wolf, Markus Dietlein, Alexander Drzezga, Carsten Kobe	37
11	Relapse Analysis of Irradiated Patients Within the HD15 Trial of the German Hodgkin Study Group 2015 ·International Journal of Radiation OncologyBiologyPhysics ·Jan Kříž, Gabriele Reinartz, Markus Dietlein, Carsten Kobe, Georg Kuhnert, Heinz Haverkamp, Uwe Haverkamp, Rita Engenhart‐Cabillic, Klaus Herfarth, Peter Lukáš, Heinz Schmidberger, S. Staar, (unknown), Christian Baues, Andreas Engert, Hans Theodor Eich	16
12	The 18F-labeled PSMA_6 compares favorably to 68Ga-labeled PSMA-HBED-CC. A first clinical study in patients with relapsed prostate cancer 2015 ·Carsten Kobe, Markus Dietlein, Georg Kuhnert, Thomas Fischer, Klaus Schomäcker, Boris D. Zlatopolskiy, Philipp Krapf, Raphael Richarz, Alexander Drzezga, Bernd Neumaier	1
13	A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma 2015 ·Blood ·Achim Rothe, Stephanie Sasse, Max S. Topp, Dennis A. Eichenauer, Horst Hummel, Katrin S. Reiners, Markus Dietlein, Georg Kuhnert, (unknown), (unknown), M. Ravic, Stefan Knackmuss, Jens‐Peter Marschner, Elke Pogge von Strandmann, Peter Borchmann, Andreas Engert	253
14	Assessment of Tumor Size Reduction Improves Outcome Prediction of Positron Emission Tomography/Computed Tomography After Chemotherapy in Advanced-Stage Hodgkin Lymphoma 2014 ·Journal of Clinical Oncology ·Carsten Kobe, Georg Kuhnert, Deniz Kahraman, Heinz Haverkamp, Hans‐Theodor Eich, Mareike Franke, Thorsten Persigehl, Susanne Klutmann, Holger Amthauer, Andreas Bockisch, Regine Kluge, Hans‐Heinrich Wolf, David Maintz, Michael Fuchs, Peter Borchmann, Volker Diehl, Alexander Drzezga, Andreas Engert, Markus Dietlein	44
15	18-Fluorodeoxyglucose positron emission tomography/computed tomography for assessment of response to brentuximab vedotin treatment in relapsed and refractory Hodgkin lymphoma 2013 ·Leukemia & lymphoma ·Deniz Kahraman, Sebastian Theurich, Achim Rothe, Georg Kuhnert, Stephanie Sasse, Christoph Scheid, Markus Dietlein, Alexander Drzezga, Michael von Bergwelt‐Baildon, Carsten Kobe	17
16	Early Interim PET/CT beim Hodgkin-Lymphom des Erwachsenen - Von der Risikostratifizierung zur Therapiestratifizierung 2013 ·Der Nuklearmediziner ·Markus Dietlein, Georg Kuhnert, Deniz Kahraman, Andreas Engert, Peter Borchmann, Michael Fuchs, Christian Baues, Hans Theodor Eich, Alexander Drzezga, Carsten Kobe	0
17	Brentuximab vedotin (SGN-35) in patients with transplant-naive relapsed/refractory Hodgkin lymphoma 2013 ·Leukemia & lymphoma ·Stephanie Sasse, Achim Rothe, Helen Goergen, Dennis A. Eichenauer, Andreas Lohri, Stephan Kreher, Ulrich Jäger, Christopher Bangard, Georg Kuhnert, Boris Böll, Bastian von Tresckow, Andreas Engert	33
18	Relapse Analysis After Radiation Therapy of PET-Positive Residual Tumors of Patients With Advanced Stage Hodgkin Lymphoma Treated in the HD15 Trial of the German Hodgkin Study Group (GHSG) 2013 ·International Journal of Radiation OncologyBiologyPhysics ·Hans‐Theodor Eich, (unknown), Gabriele Reinartz, Carsten Kobe, Georg Kuhnert, Uwe Haverkamp, Heinz Haverkamp, (unknown), Christian Baues, Andreas Engert	1
19	PET/CT zur Therapiekontrolle beim Hodgkin-Lymphom des Erwachsenen: Hängt die Indikation zur Strahlentherapie vom Ergebnis der PET/CT ab? 2013 ·Der Nuklearmediziner ·Carsten Kobe, Georg Kuhnert, Deniz Kahraman, A. Holstein, (unknown), Andreas Engert, Peter Borchmann, Michael Fuchs, (unknown), (unknown), Christian Baues, Alexander Drzezga, Markus Dietlein	0
20	Large mediastinal tumor mass as a prognostic factor in Hodgkin’s lymphoma 2012 ·Strahlentherapie und Onkologie ·(unknown), Rolf‐Peter Mueller, Horst Mueller, Georg Kuhnert, Andreas Engert, Carsten Kobe, Uwe Haverkamp, Hans Theodor Eich	5

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact